Baxalta (BXLT) Tops Q3 EPS by 7c; Updates FY15 EPS Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Baxalta Announces Strong Sales and Earnings for Third Quarter Exceeding Guidance, Raises Second Half 2015 Outlook
October 29, 2015 6:41 AM EDTHigher global demand bolsters growth for companys leading hematology and immunology therapies Successfully integrating ONCASPAR acquisition into new oncology business Key milestone achievements advance pipeline toward delivering 20 new product launches by 2020 Preliminary 2016 guidance reflects positive sales momentum, strong operational performance, and Adjusted EPS of $2.15 to $2.25 per diluted share (GAAP EPS of $2.07 to $2.17 per diluted share)
BANNOCKBURN, Ill.--(BUSINESS WIRE)-- Baxalta Incorporated (NYSE: BXLT) today reported strong third quarter financial results, exceeding its... More
